Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03220217 · ClinicalTrials.gov registry record · Phase 2
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
A Phase 2 study, sponsored by Ipsen.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT03220217 is a Phase 2 study that has completed, run by Ipsen. The registered enrollment target is 29 participants.
The verdict
NCT03220217, a Phase 2 study, has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this clinical research is to confirm the optimal dose of 68Ga-satoreotide trizoxetan (68Ga-IPN01070), formerly 68Ga-OPS202, as a PET imaging agent to be used to detect and localize gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). 68Ga-IPN01070 is a radiolabelled imaging agent to be used in association with Positron-Emission-Tomography (PET). 68Ga-IPN01070 is made of two main components: 1) IPN01070, an antagonistic somatostatin analogue which binds to the somatostatin receptor (type 2) present on the surface of the tumor cells and 2) Gallium-68, a radioisotope that combined with IPN01070 can be seen in the PET scanner.
Interventions
- DRUG Satoreotide trizoxetan 5-20μg
- DRUG Satoreotide trizoxetan 30-45μg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2017-09-26 |
| Est. Completion | 2019-08-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03220217
The ClinicalTrials.gov registry entry for NCT03220217 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Satoreotide trizoxetan 5-20μg is the first listed.
NCT03220217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03220217 about?
NCT03220217 is a clinical study titled "To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)". The purpose of this clinical research is to confirm the optimal dose of 68Ga-satoreotide trizoxetan (68Ga-IPN01070), formerly 68Ga-OPS202, as a PET imaging agent to be used to detect and localize gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). 68Ga-IPN01070 is a radiolabelled imaging agen...
What is the current status of trial NCT03220217?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2017-09-26. Estimated completion is 2019-08-05.
What interventions are being tested in trial NCT03220217?
The interventions under investigation include: Satoreotide trizoxetan 5-20μg (DRUG), Satoreotide trizoxetan 30-45μg (DRUG).
Who is sponsoring clinical trial NCT03220217?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.